2026 Drug Approvals: How the FDA, China, Japan and Europe Compare

16 November 2026 | Monday | Analysis


The FDA is on course for its strongest novel-approval count in three years despite a leadership upheaval. China is now granting world-first approvals to global medicines. Japan is approving some of the year's biggest drugs before anyone else while its drug-loss list keeps growing. A region-by-region reading of what the world's regulators approved in 2026, and what it signals for 2027.

For most of the last two decades, a year in drug approvals could be summarised in a single number: how many new molecular entities the US Food and Drug Administration cleared. Europe followed a year or so later, Japan a little after that, and the rest of Asia waited its turn. 2026 is the year that sequence stopped holding.

The FDA number is still impressive. By 9 November, the agency's Center for Drug Evaluation and Research (CDER) had approved 48 novel drugs, already ahead of the 46 it managed in the whole of 2025. But the more interesting stories sit elsewhere on the map. A Takeda narcolepsy drug developed through global trials was approved in Beijing two weeks before Washington. AstraZeneca's camizestrant, GSK's bepirovirsen and Bayer's gadoquatrane all reached patients in Japan first. China approved 38 globally new drugs in the first half alone, and every one of the year's new-mechanism approvals in that period came from a Chinese developer.

This analysis works through each major regulator in turn, then pulls out the patterns that matter for companies planning their 2027 filings. A short note on definitions first: regulators count differently. The FDA's figure covers new molecular entities and new therapeutic biologics reviewed by CDER only; China's headline figure counts Class 1 innovative drugs; the European Medicines Agency reports positive opinions, which include biosimilars and generics. The numbers below are compared with that in mind, not added together.

The 2026 scoreboard at a glance

Regulator

2026 so far

Reference point

US FDA (CDER)

48 novel drugs to 9 Nov

46 in 2025; 50 in 2024; 55 in 2023

US FDA (CBER)

2 novel orphan products in H1 (Kresladi, Otarmeni)

Between 3 and 9 first-half approvals each year, 2020 to 2025

EMA (CHMP)

72 positive opinions on new medicines to October; 8 negative

104 recommended in 2025, of which 38 new active substances

China NMPA

38 Class 1 innovative drugs in H1; domestic share about 80% through Q3

Record 76 innovative drugs in 2025; 48 in 2024

Japan PMDA

33 new active substances verified to 22 Sept, at least six world firsts

66 new active ingredients in FY2024

Sources: FDA, EMA, NMPA via Xinhua and ECNS, MIIT via SCMP, Jefferies via BioSpace, BioPharma APAC first-approval tracker. Counting rules differ by regulator.

United States: a strong count from a shaken agency

Start with the paradox. 2026 has been one of the most turbulent years in the FDA's modern history. Commissioner Marty Makary resigned on 12 May after roughly 13 months in the job, and Kyle Diamantas, the agency's deputy commissioner for food and a lawyer by training, was named acting commissioner. The biologics centre lost its director and then its acting head of cell and gene therapy. Industry observers spent the spring warning about slower decisions and unpredictable rejections.

And yet the output did not collapse. BioSpace counted 26 novel approvals across the agency in the first half, up from 19 in the same period of 2025, even as total verdicts dipped slightly and rejections rose. The second half then ran hotter still. September alone delivered nine CDER approvals, the busiest month of the year, and October and early November added Asahi Kasei's Hovilpri (pritelivir), GSK's Hibsago (bepirovirsen) and Bayer's Sunharbo (asundexian). At the current rate CDER will finish somewhere in the low to mid fifties, its best year since 2023.

The explanation is mostly structural. Review divisions held to their PDUFA goal dates even while leadership churned, and applications filed in 2025 were already deep in the queue. The approvals of 2026 are a lagging indicator of a pipeline that was built years ago. The real test of the turmoil will show up in the 2027 and 2028 numbers, when applications filed during this year's uncertainty reach their action dates.

What the FDA actually approved

Counting approvals tells you how busy the agency was. Reading the list tells you where medicine is going, and five themes stand out.

Pills replacing injections. The headline launch of the year was Eli Lilly's Foundayo (orforglipron), an oral GLP-1 for obesity approved on 1 April as the first new molecular entity cleared under the Commissioner's National Priority Voucher programme. It was joined by Johnson & Johnson's Icotyde (icotrokinra), an oral peptide blocking the IL-23 receptor in psoriasis, and Merck's Lipfendra (enlicitide), an oral macrocyclic peptide PCSK9 inhibitor for cholesterol. Three of the biggest commercial categories in medicine, obesity, psoriasis and lipid lowering, each gained a credible oral option to biologic injections in a single year.

A cardiovascular revival. For a decade, cardiology was the area big pharma talked about leaving. 2026 brought AstraZeneca's Baxfendy (baxdrostat), a first-in-class aldosterone synthase inhibitor for hard-to-control hypertension, alongside Lipfendra and, in November, Bayer's Sunharbo (asundexian), an oral Factor XIa inhibitor to cut stroke risk after a recent ischaemic stroke or high-risk TIA. Factor XIa had become a cautionary tale after earlier trial setbacks, so its first approval is a genuine scientific comeback.

Oncology goes after the hardest targets. Oncology remained the largest single category with around 11 novel approvals. The standouts tackle targets once called undruggable: Revolution Medicines' Rasonque (daraxonrasib), a RAS inhibitor for metastatic pancreatic cancer; Arvinas and Pfizer's Veppanu (vepdegestrant), the first approved PROTAC protein degrader; and Bristol Myers Squibb's Zenbexus (iberdomide), a cereblon-modulating degrader for myeloma. Breast cancer alone collected three new endocrine-pathway drugs: Veppanu, Celcuity's Revtorpyk (gedatolisib) and AstraZeneca's Etcamah (camizestrant).

Infectious disease is back on the list. Seven of the year's novel approvals treat infections, an unusually high share. They include GSK's Utebzi (tebipenem pivoxil), the first oral carbapenem in the US, Wockhardt's Zaynich (cefepime and zidebactam) for complicated urinary tract infections, Gilead's Hepcludex for hepatitis delta, Shionogi's Xocova for COVID-19 post-exposure prophylaxis and GSK's antisense drug bepirovirsen for chronic hepatitis B. For an AMR-weary field, two new antibacterials in one year is meaningful, even if it falls well short of need.

Rare disease keeps its grip. Around nine approvals target rare conditions, from Denali's Avlayah for Hunter syndrome, an enzyme engineered to cross the blood-brain barrier, to two different drugs for fibrodysplasia ossificans progressiva approved five weeks apart. Weekly insulins also arrived on both sides of the industry's biggest diabetes rivalry, with Novo Nordisk's Awiqli (insulin icodec) in March and Lilly's Onswik (insulin efsitora alfa) in September.

By modality, the mix leaned back towards chemistry: 35 small molecules against 13 biologics, according to one independent tracker of the FDA list. Eight approvals used the accelerated pathway, a modest number given the political pressure for speed.

CBER and the voucher experiment

The weaker part of the US story sits in the biologics centre. CBER, which regulates gene and cell therapies, approved just two novel orphan products in the first half: Rocket Pharmaceuticals' Kresladi for leukocyte adhesion deficiency type I and Regeneron's Otarmeni, the first gene therapy for genetic hearing loss. Jefferies data cited by BioSpace put that below every first half from 2020 to 2025. The mood shifted after the spring leadership changes, with the agency signalling more flexibility to sponsors such as REGENXBIO and uniQure, but the approvals from that change of tone will mostly land in 2027.

The year's most consequential policy experiment was the Commissioner's National Priority Voucher (CNPV) pilot, which targets a one to two month review instead of the usual ten months or so. By late August the FDA had listed ten approvals under the programme and one complete response letter. Otarmeni was cleared in about 61 days. Critics in Congress have called the selection process opaque, and a public hearing in June gathered calls for clearer criteria. Even so, a review clock measured in weeks is now a demonstrated reality for a select few, and every big sponsor will be lobbying for a voucher in 2027.

Europe: steady output, a new rulebook

The European Medicines Agency had a quieter year in volume terms, but not in policy. At its October meeting the CHMP recommended six new medicines, including Lilly's Foundayo, Revolution Medicines' Rasonque and Ascendis Pharma's Yuviwel for achondroplasia, taking the year's tally of positive opinions on new medicines to 72, with eight negative opinions. For context, the agency recommended 104 medicines in the whole of 2025, of which 38 contained a new active substance. With two CHMP meetings left, 2026 looks set to land in a broadly similar range.

Two details stand out. First, the gap between US and EU decisions on headline drugs is narrowing: Rasonque reached a positive CHMP opinion about seven weeks after its FDA approval, helped by a phased review under EMA's Cancer Medicines Pathfinder project. Second, Europe kept saying no when the data did not convince it, confirming on re-examination its refusal of Omeros' narsoplimab, a drug the agency judged differently from regulators elsewhere.

The bigger European story is legislative. On 28 September the Council of the EU formally adopted the Pharma Package, the most significant rewrite of EU pharmaceutical law since 2004, sending it to the European Parliament for its second reading. The baseline regulatory protection moves to eight years of data protection plus one year of market protection, with up to two further years available for meeting unmet need, running comparative trials or launching across member states. Full application is expected around 2028. For Asian companies weighing whether to file in Europe, the rules of the game are now known, and they reward early, broad launches more than before.

China: from volume to world firsts

If the FDA's story is resilience, China's is acceleration. The National Medical Products Administration approved a record 76 innovative drugs in 2025, up from 48 the year before. In the first half of 2026 it approved 38 globally new, Class 1 innovative drugs, and NMPA officials noted that the 11 new-target, new-mechanism drugs approved in that half already matched the whole of 2025. All 11 came from domestic developers. Through the first three quarters, China's Ministry of Industry and Information Technology says domestic products made up about 80% of all innovative medicines approved.

The approvals themselves have moved up the value chain. Sciwind's ecnoglutide, a cAMP-biased GLP-1 receptor agonist for weight management, was approved in March as a world first. CARsgen's satri-cel, a CAR-T for solid tumours, and SystImmune and Baili's bispecific ADC iza-bren are among the Chinese world firsts flagged by BioPharma APAC's first-approval tracker, alongside two infant RSV antibodies cleared in September.

The moment that will be remembered, though, came on 21 July. The NMPA approved Takeda's Orzeyful (oveporexton), a first-in-class oral orexin 2 receptor agonist for narcolepsy type 1. Takeda had filed in China in January, ahead of its US filing in February and Japan in March, on the back of global Phase III data. China approved it first; the FDA followed on 5 August. NMPA officials described it as the first original-target drug developed through global multicentre trials to win its first approval anywhere in China. For multinationals, the lesson is practical: China is no longer the last stop on a launch sequence. With priority review, conditional approval and a reimbursement listing that now takes about a year rather than five, it can be the first.

Money is following the science. Chinese out-licensing deals reached about USD 110 billion in the first half and roughly USD 130 billion by the end of September, close to the full-year 2025 record. That is where the caveat lies. The flood of licensing shows Western pharma trusts Chinese molecules, but most Chinese drugs still do not travel on their own passports. An ISPOR Europe 2026 analysis of 237 drugs approved by China-headquartered companies between 2015 and 2025 found only 8% had been approved outside China, and only 2% by the FDA. China's challenge for 2027 is not discovery. It is turning domestic approvals into global ones, while the BIOSECURE debate in Washington and questions about China-only clinical data hang over the path.

Japan: the first approver with a drug-loss problem

Japan delivered the year's most underrated performance. BioPharma APAC's register-verified tracker counted 33 new active substances approved by Japan's PMDA and health ministry by late September, and at least six of them were world firsts. Several are among the most important drugs of the year globally.

Japan approved them first

Drug

Company

Japan approval

FDA approval

Gadoquatrane (MRI contrast)

Bayer

23 March 2026

12 June 2026

Camizestrant (ESR1-mutant breast cancer)

AstraZeneca

19 June 2026

4 September 2026

Bepirovirsen (chronic hepatitis B)

GSK

24 August 2026 (Sakigake)

20 October 2026

Insulin efsitora alfa (weekly insulin)

Eli Lilly

16 September 2026

23 September 2026

Sources: BioPharma APAC first-approval tracker (PMDA register), FDA Novel Drug Approvals for 2026.

Alexion's gefurulimab for generalised myasthenia gravis and anselamimab for AL amyloidosis were also approved in Japan in September ahead of other markets. Bepirovirsen, approved with a functional-cure framing under the Sakigake fast-track, is the clearest demonstration that Japan's pioneer designation can now beat the FDA to market for a global product.

The paradox is that the same year saw Japan's drug-loss problem worsen. Health ministry data cited by the Yomiuri Shimbun show 86 medicines approved overseas were unavailable in Japan as of March 2023, and 28 more were added by April 2026, taking the total to roughly 114. The new pressure is American pricing policy. The Trump administration's most-favoured-nation approach references prices in countries including Japan, where new drugs launched at about 40% of US prices according to a PhRMA survey. In a July survey by the Japan Pharmaceutical Manufacturers Association, 38% of member companies said the policy was already having an impact and 56% expected it to. Eli Lilly's breast cancer drug Inluriyo, approved about nine months earlier, was still not on the market in September as price talks continued.

So Japan ends 2026 split in two. For big global companies already running Japanese patients in their pivotal trials, it is one of the fastest regulators in the world. For mid-sized and emerging biotechs weighing whether Japan is worth a filing at all, the pricing maths is getting worse. Tokyo's response, including wider acceptance of English-language filings and orphan incentives, will be one of the most important policy stories to follow in 2027.

The rest of Asia: Korea, India and the reference markets

South Korea produced two notable firsts. Curocell's anbal-cel, approved in April for relapsed or refractory large B-cell lymphoma, is the country's first domestically developed CAR-T therapy, and FutureChem's florastamin (18F), a PSMA-targeted PET agent for prostate cancer, followed days later. In September, GL Pharmtech's recoflafone for dry eye disease became the first approval under the MFDS's reformed review clock. Korean companies also reached the US list through ownership: Elevar Therapeutics, part of Korea's HLB group, won FDA approval for Lyrfigtu (lirafugratinib) in FGFR2-altered cholangiocarcinoma in September.

India's year in new approvals was thinner at home but visible abroad. Wockhardt's Zaynich became one of the year's two new US antibacterials, and Zydus-backed Sentynl's Zycubo (copper histidinate) for Menkes disease was the very first FDA novel approval of 2026. Domestically, the most significant public-health clearance was Takeda's TAK-003, reported in July as India's first dengue vaccine. The weak point is transparency: BioPharma APAC found the CDSCO's public new-drug register had not been updated since March, which makes India the hardest major market to track in real time.

Singapore's HSA and Taiwan's TFDA each logged 14 verified new active substances in the same tracker. They rarely approve first, but they remain important reference regulators for Southeast Asian launches, and their steady throughput is quietly lowering the drug lag across ASEAN.

Asia's fingerprints on the FDA list

Read the FDA's 48 approvals by where the molecule's sponsor or originator is based, and Asia's share is larger than most people assume. By our count, around 11 of the 48 trace back to Asian companies.

Origin

Count

Approvals

Japan

6

Adquey and Simtriyo (Otsuka), Xocova (Shionogi), Orzeyful (Takeda), Mimrylo (Takeda with Protagonist), Hovilpri (Asahi Kasei)

China

2

Beqalzi, sonrotoclax (BeOne Medicines); Cypsedo, cipepofol (Haisco)

India

2

Zaynich (Wockhardt); Zycubo (Sentynl, a Zydus company)

South Korea

1

Lyrfigtu (Elevar Therapeutics, HLB group)

BioSpectrum Asia analysis of the FDA Novel Drug Approvals for 2026 list to 9 November. Attribution is by sponsor or parent company and is indicative.

That count excludes the many Chinese-originated assets now sitting in Western pipelines through licensing deals, which will start arriving on the FDA list in 2027 and 2028 under American or European sponsor names. It also excludes Abbisko's pimicotinib, partnered with Merck KGaA, which was reported approved by the FDA on 10 November but had not yet appeared on the agency's list at the time of writing. The direction is clear: Asia is no longer just the place where global drugs eventually launch. It is increasingly where they come from.

Five patterns that define 2026

  • The first approval can now come from anywhere. Beijing approved Orzeyful first. Tokyo approved camizestrant, bepirovirsen and gadoquatrane first. Global sponsors are running filing strategies in parallel, and the regulator with the fastest clock wins the headline.
  • Speed has become policy. The FDA's national priority voucher, China's priority and conditional pathways, Japan's Sakigake and EMA's Pathfinder project are all variations on the same idea. Regulators are competing on review time, and that competition is not going away.
  • Convenience is a breakthrough. Oral GLP-1s, oral IL-23 blockers, oral PCSK9 inhibitors and once-weekly insulins show that changing how a drug is taken can matter as much commercially as a new mechanism.
  • Old graveyards are yielding. RAS in pancreatic cancer, Factor XIa in stroke prevention, oral carbapenems in resistant infections: several areas long written off produced approvals in the same year.
  • Pricing now shapes the launch map. Approval is only half the story. US most-favoured-nation policy is changing where and when companies launch, with Japan the first visible casualty. The approval count and the access count are drifting apart.

What to watch in 2027

The first question is the FDA. A Senate-confirmed commissioner, stable leadership at CBER and a clear future for the national priority voucher would let the agency build on a strong 2026. Continued churn would begin to show up in action dates, particularly for the gene therapies whose sponsors were encouraged to file this year.

The second is whether China's approvals start to go global under Chinese names. A Chinese-sponsored drug reaching both the FDA and EMA on its own, rather than through a licensing partner, would be a milestone worth more than another record domestic tally.

The third is Japan's answer to the pricing squeeze. If Tokyo can protect launch economics while keeping its review speed, it remains the most attractive first-approval market in Asia. If not, the drug-loss list will grow faster than the world-first list.

For companies across Asia, the practical takeaway is to plan filings as a portfolio rather than a queue. The order in which the world approves medicines is no longer fixed, and 2026 has shown that the companies willing to file early and in parallel, in Beijing, Tokyo and Washington at once, are the ones setting the pace.

News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close